The stock has a 36-month beta value of 0.42. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CERO is 0.36M, and at present, short sellers hold a 8.90% of that float. On June 17, 2025, the average trading volume of CERO was 104.26K shares.
CERO) stock’s latest price update
CERo Therapeutics Holdings Inc (NASDAQ: CERO)’s stock price has plunge by 239.55relation to previous closing price of 6.87. Nevertheless, the company has seen a 217.28% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-17 that SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that deploy phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has granted CERo’s Orphan Drug Designation (ODD) for the company’s lead drug candidate CER-1236, for the treatment of acute myeloid leukemia (AML). CER-1236 is an innovative therapy that engineers a cancer patient’s own T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells.
CERO’s Market Performance
CERo Therapeutics Holdings Inc (CERO) has seen a 217.28% rise in stock performance for the week, with a 99.32% gain in the past month and a 28.13% surge in the past quarter. The volatility ratio for the week is 6.41%, and the volatility levels for the past 30 days are at 6.41% for CERO. The simple moving average for the past 20 days is 138.34% for CERO’s stock, with a -79.18% simple moving average for the past 200 days.
CERO Trading at 83.13% from the 50-Day Moving Average
After a stumble in the market that brought CERO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.40% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CERO starting from YK Bioventures Opportunities G, who sale 2,998,908 shares at the price of $0.06 back on Dec 13 ’24. After this action, YK Bioventures Opportunities G now owns 13,005,169 shares of CERo Therapeutics Holdings Inc, valued at $179,934 using the latest closing price.
YK Bioventures Opportunities G, the 10% Owner of CERo Therapeutics Holdings Inc, sale 1,614,541 shares at $0.07 during a trade that took place back on Dec 12 ’24, which means that YK Bioventures Opportunities G is holding 16,004,077 shares at $113,018 based on the most recent closing price.
Stock Fundamentals for CERO
The total capital return value is set at -125.55. Equity return is now at value -4090.08, with -114.10 for asset returns.
Based on CERo Therapeutics Holdings Inc (CERO), the company’s capital structure generated 1.32 points at debt to capital in total, while cash flow to debt ratio is standing at -3.77. The debt to equity ratio resting at -4.15. The interest coverage ratio of the stock is 1723.6.
Currently, EBITDA for the company is -6.57 million with net debt to EBITDA at 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.73.
Conclusion
To sum up, CERo Therapeutics Holdings Inc (CERO) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
